US · ICUI · MEDICAL - INSTRUMENTS & SUPPLIES
ICU Medical, Inc. (ICUI) intrinsic value and stock valuation
$172.52as of 2026-11-21 · Mkt cap 4.61B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
ICU Medical, Inc. DCF and intrinsic value
InvestorsCraft values ICUI with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from ICUI’s statements →
ICU Medical, Inc. Graham Number
Graham Number: $7.58d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Travere Therapeutics, Inc. (TVTX) $47.00
- LivaNova PLC (LIVN) $90.73
- Haemonetics Corporation (HAE) $120.16
- Arcutis Biotherapeutics, Inc. (ARQT) $26.36
- Disc Medicine, Inc. (IRON) $75.14
- Tarsus Pharmaceuticals, Inc. (TARS) $73.01
- Prestige Consumer Healthcare Inc. (PBH) $49.63
- Heartflow, Inc. Common Stock (HTFL) $46.69
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.23B | $2.38B | $2.26B | $2.28B | $1.32B |
| Operating income | $107M | $43M | $22.8M | -$-42.9M | $123.3M |
| Net income | $730K | -$-117.69M | -$-29.66M | -$-74.29M | $103.1M |
| EPSd | $29.3K | -$-4.83M | -$-1.23M | -$-3.11M | $4.74M |
| Operating cash flow | $179.9M | $204M | $166.2M | -$-62.13M | $267.5M |
| Capital expenditure | -$-88.04M | -$-79.37M | -$-93.67M | -$-99.33M | -$-81.17M |
| Free cash flow | $91.8M | $124.7M | $72.5M | -$-161.46M | $186.4M |
| Total assets | $4.05B | $4.2B | $4.38B | $4.52B | $1.88B |
| Total debt | $1.39B | $1.64B | $1.7B | $1.73B | $45.1M |
| Net debt | $1.08B | $1.33B | $1.45B | $1.53B | -$-507.78M |
| Total equity | $2.12B | $1.97B | $2.12B | $2.09B | $1.62B |
| Cash and short-term investments | $308M | $308.6M | $254.7M | $213M | $567.3M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.23B | $2.38B | $2.26B | $2.28B | $1.32B |
| Cost of revenue | $1.41B | $1.56B | $1.52B | $1.58B | $824.8M |
| Gross profit | $819.7M | $824.8M | $739.9M | $697.8M | $491.5M |
| Research and development expenses | $87.5M | $88.6M | $85.3M | $93M | $47.5M |
| Selling, general and administrative expenses | $625.2M | $638.8M | $606.7M | $608.4M | $302.6M |
| Other expenses | $0.00 | $54.4M | $25M | $39.3M | $18.2M |
| Operating expenses | $712.7M | $781.8M | $717.1M | $740.7M | $368.3M |
| Cost and expenses | $2.12B | $2.34B | $2.24B | $2.32B | $1.19B |
| Interest income | $10.3M | $10.8M | $7.51M | $4.43M | $2.84M |
| Interest expense | $105.4M | $106.5M | $102.7M | $70.8M | $860K |
| Depreciation and amortization | $218M | $2.44M | $228.8M | $235.2M | $99.3M |
| Ebitda | $326.5M | $43M | $253.2M | $191.6M | $223.5M |
| Operating income | $107M | $43M | $22.8M | -$-42.9M | $123.3M |
| Total other income/expenses, net | -$-103.78M | -$-108.98M | -$-101.12M | -$-71.51M | -$-60K |
| Income before tax | $3.17M | -$-66.01M | -$-78.3M | -$-114.41M | $123.2M |
| Income tax expense | $2.44M | $51.7M | -$-48.64M | -$-40.12M | $20.1M |
| Net income | $730K | -$-117.69M | -$-29.66M | -$-74.29M | $103.1M |
| Weighted average shares outstanding | $24.6M | $24.4M | $24.1M | $23.9M | $21.2M |
| Weighted average diluted shares outstanding | $24.9M | $24.4M | $24.1M | $23.9M | $21.8M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $308M | $308.6M | $254.7M | $213M | $567.3M |
| Net receivables | $180.5M | $202.7M | $182.2M | $246.9M | $124.8M |
| Inventory | $615.9M | $584.7M | $709.4M | $696M | $290.2M |
| Total current assets | $1.18B | $1.44B | $1.22B | $1.24B | $1.03B |
| Property, plant and equipment, net | $506.3M | $499.3M | $685.5M | $713.6M | $510.9M |
| Goodwill and intangible assets | $2.13B | $2.17B | $2.34B | $2.43B | $231.8M |
| Long-term investments | $131.6M | $8.76M | $3.12M | $3.69M | $7.86M |
| Total non-current assets | $2.86B | $2.76B | $3.16B | $3.28B | $850.9M |
| Total assets | $4.05B | $4.2B | $4.38B | $4.52B | $1.88B |
| Accounts payable | $154.4M | $148M | $150M | $215.9M | $81.1M |
| Short-term debt | $34.7M | $66.7M | $71.2M | $47.9M | $9.01M |
| Deferred revenue | $33.8M | $30.4M | $31.6M | $30.8M | $12.7M |
| Total current liabilities | $498.9M | $556.2M | $481.8M | $494.6M | $200.8M |
| Long-term debt | $1.36B | $1.57B | $1.63B | $1.69B | $36M |
| Deferred revenue, non-current | $0.00 | $9.04M | $10.6M | $16.2M | $0.00 |
| Total non-current liabilities | $1.43B | $1.68B | $1.77B | $1.93B | $63.9M |
| Capital lease obligations | $47.7M | $58.8M | $75.1M | $80.9M | $45.1M |
| Total liabilities | $1.93B | $2.24B | $2.26B | $2.43B | $264.7M |
| Common stock | $2.47M | $2.45M | $2.41M | $2.4M | $2.13M |
| Retained earnings | $690.9M | $690.2M | $807.9M | $837.5M | $911.8M |
| Accumulated other comprehensive income (loss) | -$-34.63M | -$-139.4M | -$-53.08M | -$-80.98M | -$-19.27M |
| Total equity | $2.12B | $1.97B | $2.12B | $2.09B | $1.62B |
| Total investments | $131.6M | $8.76M | $3.62M | $7.92M | $22.3M |
| Total debt | $1.39B | $1.64B | $1.7B | $1.73B | $45.1M |
| Net debt | $1.08B | $1.33B | $1.45B | $1.53B | -$-507.78M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $730K | -$-117.69M | -$-29.66M | -$-74.29M | $103.1M |
| Depreciation and amortization | $200.7M | $240.9M | $228.8M | $235.2M | $89.7M |
| Stock-based compensation | $55.8M | $46.9M | $40.6M | $36M | $27.3M |
| Change in working capital | -$-90.04M | -$-2.57M | -$-135.6M | -$-303.73M | $15M |
| Accounts receivable | $8.88M | -$-46.84M | $48.6M | -$-19.15M | $13.8M |
| Inventory | -$-26.25M | $16.8M | -$-6.08M | -$-201.09M | $20.8M |
| Accounts payable | $7M | $12.5M | -$-68.3M | $37.5M | $2.35M |
| Net cash provided by operating activities | $179.9M | $204M | $166.2M | -$-62.13M | $267.5M |
| Investments in property, plant and equipment | -$-88.04M | -$-79.37M | -$-83.89M | -$-90.31M | -$-68.54M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | -$-1.84B | -$-14.45M |
| Net cash used for investing activities | $122.2M | -$-88.96M | -$-87.95M | -$-1.91B | -$-90.69M |
| Common stock issued | $6.11M | $10.9M | $4.02M | $8.79M | $9.37M |
| Common stock repurchased | -$-8.77M | -$-11.99M | -$-9.35M | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-311.52M | -$-55.8M | -$-35.98M | $1.64B | -$-16.87M |
| Net change in cash | -$-600K | $54.3M | $45.4M | -$-344.04M | $156.7M |
| Cash at end of period | $308M | $308.6M | $254.2M | $208.8M | $552.8M |
| Operating cash flow | $179.9M | $204M | $166.2M | -$-62.13M | $267.5M |
| Capital expenditure | -$-88.04M | -$-79.37M | -$-93.67M | -$-99.33M | -$-81.17M |
| Free cash flow | $91.8M | $124.7M | $72.5M | -$-161.46M | $186.4M |
Line items
Line items
Line items
About ICU Medical, Inc.
ICU Medical, Inc., operating globally through its subsidiaries, is a medical technology firm that specializes in the development, manufacture, and sale of devices for both infusion therapy and critical care. Their extensive product line for infusion therapy encompasses: Needlefree Connectors: Such as the MicroClave, MicroClave Clear, and NanoClave brands. Catheter Maintenance & Disinfection: Including Neutron patency devices and SwabCap/SwabTip disinfecting caps. Hemodialysis Solutions: Like Tego connectors and ClearGuard HD antimicrobial caps. Hazardous Drug Handling: With closed system transfer devices (ChemoClave, ChemoLock) and the Diana compounding system for safe preparation. They also provide a comprehensive range of intravenous (IV) solutions, diluents, and irrigation fluids, available in diverse packaging options like flexible containers and pour bottles. These include common formulations such as sodium chloride, dextrose, balanced electrolytes, lactated ringer's, mannitol, and sterile water, alongside specialized irrigation solutions like acetic acid and glycine. In medication management, ICU Medical offers sophisticated infusion pumps, including the Plum 360 and LifeCare PCA brands. Its advanced ICU Medical MedNet software enhances medication safety by integrating smart pumps with hospital electronic health records (EHRs), asset tracking, and alarm notification platforms. Accompanying professional services are also provided. For critical care environments, their portfolio features: Hemodynamic Monitoring: Systems like Cogent 2-in-1 and CardioFlo. Cardiac Output & Oximetry: TDQ, OptiQ, and TriOx catheters. Blood Pressure Transducers: Such as Transpac. Blood Sampling Systems: Including the SafeSet closed blood sampling and conservation systems. The company distributes its products to a wide spectrum of healthcare providers, including acute care hospitals, wholesalers, ambulatory clinics, and various alternate site facilities such as outpatient clinics, home healthcare services, and long-term care centers. Established in 1984, ICU Medical maintains its headquarters in San Clemente, California.
- CEO
- Vivek Jain
- Employees
- 13K
- Beta
- 0.76
Included in
Explore
Frequently asked questions
What is the intrinsic value of ICU Medical, Inc. (ICUI)?
ICU Medical, Inc. (ICUI) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is ICUI undervalued?
ICUI trades at a price of $172.52 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.